Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 88 Breast Neoplasms 49 Prostatic Neoplasms 43 Squamous Cell Carcinoma of Head and Neck 34 Lung Neoplasms 24 Stomach Neoplasms 19 Neoplasms 19 Neoplasm Metastasis 17 Head and Neck Neoplasms 17 Parkinson Disease 4, Autosomal Dominant Lewy Body 14 Urinary Bladder Neoplasms 13 Carcinoma, Transitional Cell 11 Triple Negative Breast Neoplasms 10 Ovarian Neoplasms 8 Endometrial Neoplasms 8 Carcinoma, Squamous Cell 8 Adenocarcinoma 8 Non-Muscle Invasive Bladder Neoplasms 7 HER2-positive Breast Cancer 7 Prostatic Neoplasms, Castration-Resistant 6 Melanoma 6 Carcinoma 6 Small Cell Lung Carcinoma 5 Nasopharyngeal Carcinoma 5 Esophageal Squamous Cell Carcinoma 5 Esophageal Neoplasms 5 Advanced Solid Tumors 5 Uterine Cervical Neoplasms 4 Sarcoma 4 Oropharyngeal Neoplasms 4

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Related Cognitive Decline × Docetaxel × 1 year × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡